Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / COM
-
Number of holders
-
163
-
Total 13F shares, excl. options
-
20,353,887
-
Shares change
-
+1,506,681
-
Total reported value, excl. options
-
$2,906,331,474
-
Value change
-
+$221,979,092
-
Put/Call ratio
-
68%
-
Number of buys
-
94
-
Number of sells
-
-69
-
Price
-
$142.68
Significant Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q2 2016
230 filings reported holding ICPT - INTERCEPT PHARMACEUTICALS IN - COM as of Q2 2016.
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) has 163 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20,353,887 shares
.
Largest 10 shareholders include FMR LLC (3,690,024 shares), AMERIPRISE FINANCIAL INC (3,006,293 shares), Capital World Investors (2,053,959 shares), Carmignac Gestion (1,993,592 shares), VANGUARD GROUP INC (1,149,749 shares), ORBIMED ADVISORS LLC (1,120,000 shares), JPMORGAN CHASE & CO (829,438 shares), STATE STREET CORP (520,567 shares), HIGHFIELDS CAPITAL MANAGEMENT LP (508,232 shares), and BlackRock Fund Advisors (477,108 shares).
This table shows the top 163 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.